IL-23 p19 drugs for Psoriasis

8 tracked IL-23 p19 drugs in the Psoriasis race. The class explanation lives on the IL-23 p19 page; the full indication pipeline across every mechanism is on the Psoriasis page.

3 approved / phase 43 Phase 32 Phase 2

Head-to-head evidence: Avrukibart vs HS-20137 · Avrukibart vs QL2106 · Avrukibart vs SHR-1139 · Avrukibart vs guselkumab · Avrukibart vs picankibart · Avrukibart vs risankizumab

The roster

← all IL-23 p19 drugs